Andrew Rule

@wisit661 @HerrmannMd @FenoglioRoberta @SethiRenalPath @LeticiaRolonMD @GarovicVesna @PepaSolerR @MayoClinicNeph Yes, we really enjoyed our visit as well!

@HerrmannMd @FenoglioRoberta @SethiRenalPath @LeticiaRolonMD @GarovicVesna @PepaSolerR @AndrewRuleMD @MayoClinicNeph Thank you 🙏🏻 for wonderful meeting! 😊😃

Thanks Dr @FenoglioRoberta , Dr Sciascia and Dr Roccatello 29º CONGRESSO PATOLOGIA IMMUNE E MALATTIE ORFANE 2026 G. BOSCO HUB HOSPITAL - TURIN meets MAYO CLINIC

Insightful AI-focused session at the 29th Congress on Immune Pathology and Orphan Diseases 2026 in Turin, Italy. @MayoClinicNeph Prof Andrew Rule, MD, delivered a forward-looking talk on “The Use of AI-Based Image Analysis to Improve Kidney Care in Patients.” @AndrewRuleMD

Spatial Mass Spectrometry-Based Proteomic Analysis of Normal-Appearing Glomeruli from Young and Old Adults @AndrewRuleMD @asnpublications journals.lww.com/kidney360/full…

Congratulations, Dr. Navin Gupta, on receiving NIH/NIDDK funding for your Innovative Science Accelerator (ISAC) proposal! This is an outstanding achievement and a great reflection of your dedication to advancing kidney science. Our division is proud to celebrate your success.

Associations Between Deep Learning-Derived Fat, Muscle, and Bone Measures From Abdominal Computed Tomography Scans and Fall Risk in Persons Aged 20 Years or Older @AndrewRuleMD mcpdigitalhealth.org/article/S2949-…

"We thank the reviewers for their helpful suggestions"

A Drug-Wide Association Study on Medications Associated With Cystatin C Estimated GFR bit.ly/41OCrjy @LAInker @SaulBlecker @leorahorwitzmd @meg21212 @jjcarrero1

The CKD awareness publication in JAMA Cardiology is really the furthest thing from novel. If anything, I am surprised that we continue to talk about this topic. The much more interesting question is how many people with eGFR-defined CKD would benefit from knowing that they have a disease that could (but usually will not) end in kidney failure.

Wonderful talk by @AndrewRuleMD , @ASNKidney Kidney Week 2025 on “Quantitative Morphometrics and Nomograms for Predicting Kidney Transplant Outcomes.” 👏 insightful perspectives on quantitative morphometrics objectively determine CKD severity using histology or imaging

Having dinner with @GlassockJ who is telling us about going to ASN Renal Week in 1967 (and he has been to everyone since then).

Back when i was a professor, early on I used to get bad reviews occasionally. My institution was extremely critical of this. So, what did I discover was the easy solution? I watered down my course and made everything easier. Magically, I started to get near perfect evaluations in what was a symbiotic hustle. Teach an easy course, crack a few jokes during lecture, and give everyone an A --> good evaluations from students. And students evals are the only way teaching is judged. Of course, students learned much back in the days when I hassled them more with hard projects.

@kidney_boy Past dosing algorithms were based on C-G equation. Switching to a contemporary equation is fine as long you also fit pharmacokinetic models to determine the optimal dosing with the equation. Unfortunately this has not been done with most drugs. journals.lww.com/ccmjournal/abs…

It’s 2025 and we’re still dosing drugs like it’s 1976. The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations. 🧮 pbfluids.com/2025/10/cockcr…

📖 This weekend don't miss our @KIReports #ISNFridaySelection: Kidney Lower Podocyte Number per Glomerulus Associates With Progressive CKD kireports.org/article/S2468-…

@SherriKEdman I heard the same from both my kids there

My Grove City kid just called me. The campus has been evacuated because of some police related situation.

Perspective by Roberto F. Nicosia and Paolo Cassoli: Malpighi’s Forgotten Drawings of Renal Glomeruli bit.ly/4lWCWyY

As always, a great Annual #Hypertension2025 meeting.
Here are some key take-home points for hypertension care across all settings (primary care & specialty care): 1️⃣ BP treatment goal <130/80 mmHg.
Ideal: <120/80 mmHg for high CVD risk patients.

I thoroughly enjoyed the Computational Nephrology conference @RWTH led by Peter Boor. I got to ask lots of questions about interesting research and even got an award for it!

CKD (definition) and aging: time to move forward... with @AndrewRuleMD @GlassockJ Sacha Denic Kidney aging and chronic kidney disease—another perspective academic.oup.com/ndt/article/40…

🥇 Today, NIH has released its implementation plan for incorporating gold standard science into everything we do. The plan incorporates the 9 tenets of gold standard science adopted by the U.S. Government and aligns with @HHSgov’s framework for achieving these principles. Read more ➡️ bit.ly/461VIAi

@ronrule Industry needs to make a profit. They fund engineering. Industry benefits from science but it is too expensive and high risk for industry to fund much of science. You can argue government should have other priorities, but industry won’t fill the gap.

@AndrewRuleMD The people who want to sell you the cure can fund that too.

We give taxpayer money to universities to fund medical research. Then the universities patent their discoveries and sell or license it to big pharma. Then big pharma sells it to us for a profit. Even though we paid for the research. Why did anyone think this was a good idea?